Troxacitabine (BCH4556; SGX145; SPD758)

Description: Troxacitabine, formerly known as BCH-4556; SGX-145; SPD-758; beta-L-OddC, is a potent DNA polymerase inhibitor with the potential for the treatment of acute myeloid leukemia (AML) and solid. In comparison with gemcitabine, troxacitabine was more efficacious against Panc-01 and was equally active against MiaPaCa. Troxacitabine has a unique metabolic and pharmacokinetic profile and significant antileukemic activity. Troxacitabine merits further study in hematologic malignancies.

References: Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, Peters GJ. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13; 3:732. doi: 10.1186/2193-1801-3-732. eCollection 2014. PubMed PMID: 25674464; PubMed Central PMCID: PMC4320143.